Along these lines, a recent phase II clinical trial demonstrated that an antisense oligonucleotide targeting hepatic ANGPTL3 (vupanorsen) led to reduction in circulating TGs and LDL in healthy and T2D individuals (71). Here, ANGPTL3 is linked to type 2 diabetes mellitus.